Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 24, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â top tenÂ
It’s Friday again, and this week in pharma has seen a slew of positive clinical trial results released in Crohn’s disease, breast cancer and multiple sclerosis, all of which were of big interest to our readers. This week also saw the approval of the first European cancer biosimilar, and some disconcerting news from Takeda.
Check out the Top Ten most popular articles on Pharmafile.com this week!
10. Faulty batch of Takeda’s paracetamol discovered in Denmark
Takeda has announced a recall of a batch of its paracetamol tablets, named Pamol, in Denmark after two packs were found to be contaminated with a different drug.
9. Takeda and TiGenix announce successful trial of Crohn’s disease drug
Takeda and TiGenix announced Phase 3 results from a trial looking into the investigational compound Cx601, a treatment for refractory complex perianal fistulas in sufferers of Crohn’s disease.
8. Top five European countries by pharmaceutical spending per capita
We arranged the top five European countries by the levels of expenditure upon pharmaceuticals, not all are from the largest countries and there’s a surprise omission.
7. First biosimilar for European cancer treatment given approval
The first biosimilar will be made available in Europe to match the indications of Roche’s best-selling cancer drug, Rituxan.
6. The future of generic drugs and strategies for commercial success
The US continues to be the largest generic drugs market by revenue but GBI Research examine whether that will continue to be the case looking forward to 2022.
5. New Managing Director of UK & Ireland for Novartis
Novartis announced the appointment of Haseeb Ahmad as Managing Director for UK & Ireland. He joins from MSD, known as Merck in North America, where he performed the role of Managing Director for Greece, Cyprus and Malta.
4. AstraZeneca’s drug scores positive results against chemo in breast cancer
AstraZeneca announced that its drug, Lynpara (olaparib), had positive results for a recent Phase 3 trial when tested against standard treatment of chemotherapy in patients suffering from HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
3. Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis
Celgene’s drug, ozanimod, has achieved positive results in a Phase 3 trial – pointing towards it entering the market as a first-in-class treatment.
2. AstraZeneca sells off cancer drug to TerSera for $250 million
AstraZeneca has given itself a cash boost by selling the commercial rights within North America for Zoladex to TerSera therapeutics.
1. What does Trump’s victory mean for the pharma, biotech and healthcare sectors?
After his first month in office and numerous threats to big pharma, finnCap Life Sciences analysts Alex Pye and Mark Brewer deconstruct what Donald Trump’s presidency could mean for the industry.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
